Letter in response to: circulating von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality.
作者信息
Bhogal P, Paul G, Collins G, Jaffer O
机构信息
Department of Interventional Neuroradiology, The Royal London Hospital, Barts NHS Trust, Whitechapel Road, London, E1 1BB, UK.
Department, of Gastroenterology, Hepatology, Pneumology and Infectious Diseases, Katharinenhospital, Klinikum Stuttgart, Krigesbergstraße 60, 70174, Stuttgart, Germany.
出版信息
Angiogenesis. 2021 Aug;24(3):413-415. doi: 10.1007/s10456-021-09790-w. Epub 2021 Jun 8.
Abstract
摘要
相似文献
1
Letter in response to: circulating von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality.致编辑的信：循环血管性血友病因子和高分子量多聚体作为内皮损伤标志物可预测COVID-19患者的院内死亡率
Angiogenesis. 2021 Aug;24(3):413-415. doi: 10.1007/s10456-021-09790-w. Epub 2021 Jun 8.
2
Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality.循环血管性血友病因子和高分子量多聚体作为内皮损伤标志物可预测COVID-19患者的院内死亡率。
Angiogenesis. 2021 Aug;24(3):505-517. doi: 10.1007/s10456-020-09762-6. Epub 2021 Jan 15.
3
Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy.子痫前期和妊娠期 COVID-19 内皮和血管生成特征的差异和相似之处。
Am J Obstet Gynecol. 2022 Aug;227(2):277.e1-277.e16. doi: 10.1016/j.ajog.2022.03.048. Epub 2022 Mar 26.
4
Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance.血管性血友病因子胶原结合能力可预测新冠病毒肺炎患者的院内死亡率：基于血管性血友病因子/含凝血酶敏感蛋白基序的去整合素样金属蛋白酶13比例失衡的见解
Angiogenesis. 2021 Aug;24(3):407-411. doi: 10.1007/s10456-021-09789-3. Epub 2021 May 11.
5
Invited commentary to: ADAMTS13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19 by Tiffany Pascreau et al. Letter to the Editors-in-Chief, Thrombosis Research.蒂芙尼·帕斯克罗等人所著《ADAMTS13缺乏与COVID-19患者血管性血友病因子多聚体的异常分布相关》的特邀评论。致《血栓形成研究》主编的信。
Thromb Res. 2021 Aug;204:141-142. doi: 10.1016/j.thromres.2021.02.030. Epub 2021 Mar 3.
6
ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19.ADAMTS 13缺乏与新型冠状病毒肺炎患者血管性血友病因子多聚体的异常分布有关。
Thromb Res. 2021 Aug;204:138-140. doi: 10.1016/j.thromres.2021.02.008. Epub 2021 Feb 9.
7
Obstetric outcomes in pregnant COVID-19 women: the imbalance of von Willebrand factor and ADAMTS13 axis.妊娠期 COVID-19 孕妇的产科结局：血管性血友病因子和 ADAMTS13 轴的失衡。
BMC Pregnancy Childbirth. 2022 Feb 21;22(1):142. doi: 10.1186/s12884-022-04405-8.
8
Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19.重组 ADAMTS13 降低重症 COVID-19 患者血浆中异常上调的 von Willebrand 因子。
Thromb Res. 2021 May;201:100-112. doi: 10.1016/j.thromres.2021.02.012. Epub 2021 Feb 18.
9
Role of von Willebrand Factor in COVID-19 Associated Coagulopathy.血管性血友病因子在 COVID-19 相关凝血障碍中的作用。
J Appl Lab Med. 2021 Sep 1;6(5):1305-1315. doi: 10.1093/jalm/jfab042.
10
Insights Into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13.免疫血栓形成的新见解：中性粒细胞胞外诱捕网、血管性血友病因子与 ADAMTS13 的相互作用。
Front Immunol. 2020 Dec 2;11:610696. doi: 10.3389/fimmu.2020.610696. eCollection 2020.
引用本文的文献
1
Complex Pattern of Platelet Activation/Reactivity After SARS-CoV-2 Infection.新型冠状病毒感染后血小板激活/反应性的复杂模式
Int J Mol Sci. 2024 Dec 24;26(1):49. doi: 10.3390/ijms26010049.
2
The modes of angiogenesis: an updated perspective.血管生成的模式：一个更新的视角。
Angiogenesis. 2023 Nov;26(4):477-480. doi: 10.1007/s10456-023-09895-4. Epub 2023 Aug 28.
3
Pathological angiogenesis: mechanisms and therapeutic strategies.病理性血管生成：机制与治疗策略。
Angiogenesis. 2023 Aug;26(3):313-347. doi: 10.1007/s10456-023-09876-7. Epub 2023 Apr 15.
4
Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance.血管性血友病因子胶原结合能力可预测新冠病毒肺炎患者的院内死亡率：基于血管性血友病因子/含凝血酶敏感蛋白基序的去整合素样金属蛋白酶13比例失衡的见解
Angiogenesis. 2021 Aug;24(3):407-411. doi: 10.1007/s10456-021-09789-3. Epub 2021 May 11.
本文引用的文献
1
The ADAMTS13-von Willebrand factor axis in COVID-19 patients.新冠病毒感染患者中的ADAMTS13-血管性血友病因子轴
J Thromb Haemost. 2021 Feb;19(2):513-521. doi: 10.1111/jth.15191. Epub 2020 Dec 18.
2
Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19.凝血生物标志物是 COVID-19 患者需氧量增加的独立预测因子。
J Thromb Haemost. 2020 Nov;18(11):2942-2953. doi: 10.1111/jth.15067. Epub 2020 Sep 18.
3
Letter in response to: Coagulation markers are independent predictors of increased oxygen requirements and thrombosis in COVID-19.对《凝血标志物是新型冠状病毒肺炎患者氧气需求增加和血栓形成的独立预测因素》的回应信
J Thromb Haemost. 2020 Dec;18(12):3382-3384. doi: 10.1111/jth.15080.
4
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.新型冠状病毒肺炎相关凝血病中的内皮病变：来自一项单中心横断面研究的证据
Lancet Haematol. 2020 Aug;7(8):e575-e582. doi: 10.1016/S2352-3026(20)30216-7. Epub 2020 Jun 30.
5
Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study.新冠病毒感染前抗凝治疗的影响：一项倾向评分匹配队列研究。
Blood. 2020 Jul 2;136(1):144-147. doi: 10.1182/blood.2020006941.
6
Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2.ADAMTS13和血管性血友病因子在感染新型冠状病毒的患者血栓栓塞事件中的作用。
Int J Lab Hematol. 2020 Oct;42(5):e211-e212. doi: 10.1111/ijlh.13244. Epub 2020 May 22.
7
Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial.
Am Heart J. 2004 Apr;147(4):E17. doi: 10.1016/j.ahj.2003.11.003.
Zotero 插件